Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects-A placebo controlled double blind investigation using 4 and 8mg Tolterodine extended release

Neurourology and Urodynamics

Volumn 29, Issue 3, 2010, Pages 464-469

  Mehnert, Ulrich ^a   Reitz, André ^a   Youssef, Sumaya Abo ^a   Schurch, Brigitte ^a  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bladder afferents; Bladder filling sensations; Filling cystometry; Lower urinary tract; Tolterodine ER

Indexed keywords

PLACEBO; TOLTERODINE; BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE;

ADULT; ARTICLE; BLADDER CAPACITY; BLADDER CATHETERIZATION; BLADDER FILLING; BLADDER MUSCLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOMETRY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; ETHICS; FEMALE; HUMAN; MICTURITION; PARAMETER; POSTVOID RESIDUAL URINE VOLUME; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SENSATION; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; UROFLOWMETRY; BLADDER; COMPARATIVE STUDY; PHYSIOLOGY; PROSPECTIVE STUDY; REFERENCE VALUE;

BENZHYDRYL COMPOUNDS; CRESOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PROSPECTIVE STUDIES; REFERENCE VALUES; SENSATION; URINARY BLADDER; YOUNG ADULT;

EID: 77953606991     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20743     Document Type: Article

References (30)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49.
2. Starkman JS, Dmochowski RR. Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodyn 2008;27:13-21.
3. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor- Which is the main mechanism of action? Eur Urol 2003;43:1-5.
4. Nabi G, Cody JD, Ellis G, et al. 2006. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane database of systematic reviews (Online)(4):CD003781.
5. Cardozo L, Dixon A. Increased warning time with darifenacin: A new concept in the management of urinary urgency. J Urol 2005;173:1214-1218
6. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565-578
7. De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: New insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006;25:156-161
8. Hedlund P, Streng T, Lee T, et al. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol 2007;178:326-331
9. Kim Y, Yoshimura N, Masuda H, et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 2005;65:238-242
10. Yokoyama O, Yusup A, Miwa Y, et al. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol 2005;174:2032-2036
11. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001b;40:227-235 (Pubitemid 32324452)
12. Jonas U, Hofner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: Urodynamic evaluation. The International Study Group. World J Urol 1997;15:144-151
13. Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: A dose-ranging study. Br J Urol 1998;81: 42-48
14. Stahl MM, Ekstrom B, Sparf B, et al. Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995;14:647-655
15. Wyndaele JJ, De Wachter S. Cystometrical sensory data from a normal population: Comparison of two groups of young healthy volunteers examined with 5 years interval. Eur Urol 2002;42:34-38
16. Habler HJ, Janig W, Koltzenburg M. Myelinated primary afferents of the sacral spinal cord responding to slow filling and distension of the cat urinary bladder. J Physiol 1993;463:449-460
17. Brostrom S, Jennum P, Lose G. Short-term reproducibility of cystometry and pressure-flow micturition studies in healthy women. Neurourol Urodyn 2002;21:457-460
18. Gupta A, Defreitas G, Lemack GE. The reproducibility of urodynamic findings in healthy female volunteers: Results of repeated studies in the same setting and after short-term follow-up. Neurourol Urodyn 2004;23: 311-316
19. Mortensen S, Lose G, Thyssen H. Repeatability of cystometry and pressureflow parameters in female patients. Int Urogynecol J Pelvic Floor Dysfunct 2002;13:72-75
20. Sorensen S, Gregersen H, Sorensen SM. Long term reproducibility of urodynamic investigations in healthy fertile females. Scand J Urol Nephrol 1988;114:35-41.
21. Kenton K, Lowenstein L, Simmons J, et al. Aging and overactive bladder may be associated with loss of urethral sensation in women. Neurourol Urodyn 2007a;26:981-984
22. Kenton K, Simmons J, FitzGerald MP, et al. Urethral and bladder current perception thresholds: Normative data in women. J Urol 2007b;178:189-192 discussion 192.
23. Kinn AC, Nilsson BY. Urethral sensitivity in incontinent women. Eur Urol 2005;48:116-120
24. Boy S, Schurch B,Mehnert U, et al. The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: Method and initial results. BJU Int 2007;100:574-578
25. De Laet K, De Wachter S, Wyndaele JJ. Current perception thresholds in the lower urinary tract: Sine- and square-wave currents studied in young healthy volunteers. Neurourol Urodyn 2005;24:261-266
26. De Wachter S, Wyndaele JJ. Can the sensory threshold toward electrical stimulation be used to quantify the subjective perception of bladder filling? A study in young healthy volunteers. Urology 2001;57:655-8. discussion 658-659.
27. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53.
28. de Groat WC. Integrative control of the lower urinary tract: Preclinical perspective. Br J Pharmacol 2006;147:S25-40.
29. Brynne N, Stahl MM, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: A new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997;35:287-295
30. Olsson B, Szamosi J. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet 2001a;40:135-143.